^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1265P - IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
Published date:
09/14/2020
Excerpt:
In the randomised, phase III IMpower150 study, atezolizumab (A) + bevacizumab (B) + carboplatin/paclitaxel (CP) chemotherapy significantly prolonged PFS and OS vs BCP in patients (pts) with first-line non-squamous NSCLC. We evaluated the efficacy of A and/or B with CP in pts with and without the KRAS mutation and according to STK11/KEAP1 status in IMpower150....KRAS mut pts treated with ABCP derived improvement in OS and PFS benefit compared with pts treated with BCP and showed numerical improvement vs pts treated with ACP. In KRAS mut pts, ABCP provided survival benefit regardless of STK11 and KEAP1 status.
Secondary therapy:
carboplatin + paclitaxel
Trial ID:
